Alnylam Pharmaceuticals Inc.'s patisiran seems to be on course to become the standard of care for hereditary ATTR (hATTR) amyloidosis after the full data set from the APOLLO study on the first RNAi therapeutic to succeed in a late-stage trial were unveiled to acclaim at a conference in Paris.
In September, the top-line results from the APOLLO study led to a 52% leap in Alnylam's share price and the full results prompted a 20% jump just during the 20-minute...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?